NCT01127295

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2,000 (actual)
• Sponsor: Institut Claudius Regaud · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a biomedical study of interventional type, multicenter, inter-regional. Patients with hormono-depending breast cancer, for which an indication of adjuvant hormonotherapy treatment (according to the current treatments) was retained, will be enrolled in this study. The main objective is to estimate the correlations between pharmacokinetic and pharmacogenetic parameters of adjuvant hormonal breast cancer treatment, during the first 3 years.

Conditions

• Hormono-depending Adjuvant Breast Cancer

Interventions

Type	Name	Description
DRUG	Tamoxifen, Letrozole, Anastrozole or Exemestane	Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years

Timeline

• Start date: 2010-06-17
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2010-05-20
• Last updated: 2026-04-14

Locations

24 sites across 1 country: France